{"id":"prevnar-20-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"20-30","effect":"Injection site erythema"},{"rate":"15-25","effect":"Injection site swelling"},{"rate":"20-30","effect":"Myalgia"},{"rate":"15-25","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"5-15","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsules from 20 different serotypes of pneumococcus conjugated to a carrier protein, which enhances immunogenicity. This conjugation allows the vaccine to trigger both T-cell and B-cell responses, providing protection against invasive pneumococcal disease and pneumococcal pneumonia caused by these serotypes. The expanded serotype coverage (compared to earlier pneumococcal conjugate vaccines) aims to provide broader protection against circulating pneumococcal strains.","oneSentence":"Prevnar 20 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 20 serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:58.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in adults aged 18 years and older"},{"name":"Prevention of pneumococcal pneumonia in adults aged 18 years and older"}]},"trialDetails":[{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT07425392","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-02-09","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT06077656","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2023-10-25","conditions":"Pneumococcal Vaccines","enrollment":220},{"nctId":"NCT07284654","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2025-12-01","conditions":"Pneumococcal Vaccines","enrollment":4000},{"nctId":"NCT07023081","phase":"PHASE1","title":"A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-06-15","conditions":"Pneumococcal Disease","enrollment":200},{"nctId":"NCT06622109","phase":"","title":"A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-11-25","conditions":"Pneumococcal Disease","enrollment":1100},{"nctId":"NCT06760208","phase":"","title":"A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-13","conditions":"Pneumococcal Immunization, Safety","enrollment":660},{"nctId":"NCT06177912","phase":"PHASE3","title":"A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-18","conditions":"Pneumococcal Infection","enrollment":882},{"nctId":"NCT06782282","phase":"","title":"A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-01-20","conditions":"Community-Acquired Pneumonia (CAP)","enrollment":22234435},{"nctId":"NCT06531538","phase":"PHASE2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-07-30","conditions":"Pneumococcal Disease","enrollment":225},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT06049134","phase":"PHASE4","title":"Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-06","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT07252791","phase":"PHASE4","title":"Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-16","conditions":"Autoimmune Rheumatologic Disease","enrollment":114},{"nctId":"NCT06128915","phase":"PHASE4","title":"The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses","status":"RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2024-01-08","conditions":"Aging","enrollment":60},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484},{"nctId":"NCT07019909","phase":"PHASE1","title":"A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-07-06","conditions":"Pneumococcal Disease","enrollment":400},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT07428759","phase":"PHASE1","title":"Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-10","conditions":"Pneumonia, Bacterial","enrollment":120},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT05183854","phase":"PHASE2","title":"Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT07247188","phase":"PHASE3","title":"Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT05452941","phase":"","title":"A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-10-27","conditions":"Pneumonia","enrollment":12500},{"nctId":"NCT06720038","phase":"PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2024-11-25","conditions":"Pneumococcal Vaccines","enrollment":905},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT05417165","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Seema Bhat","startDate":"2023-09-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":80},{"nctId":"NCT07105722","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-12","conditions":"Pneumonia, Bacterial","enrollment":127},{"nctId":"NCT06822907","phase":"PHASE4","title":"Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-01","conditions":"Acute Febrile Illness, Pneumococcal Infections","enrollment":1052},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT06678620","phase":"PHASE2","title":"Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-20","conditions":"Pneumococcal Infectious Disease","enrollment":992},{"nctId":"NCT05512819","phase":"PHASE3","title":"A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-16","conditions":"Pneumococcal Disease","enrollment":541},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT07135427","phase":"PHASE4","title":"Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-09-03","conditions":"Alpha 1-Antitrypsin, COPD, Antibody Deficiency","enrollment":30},{"nctId":"NCT05412030","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-06-16","conditions":"Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":388},{"nctId":"NCT06182124","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-12-20","conditions":"Pneumococcal Disease","enrollment":558},{"nctId":"NCT06838000","phase":"PHASE3","title":"Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-02-28","conditions":"Pneumococcal Infections","enrollment":1268},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT05844423","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2023-03-29","conditions":"Pneumococcal Vaccines","enrollment":802},{"nctId":"NCT06524414","phase":"PHASE2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-07-25","conditions":"Pneumococcal Disease","enrollment":605},{"nctId":"NCT04078997","phase":"","title":"An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2019-07-21","conditions":"13-valent Pneumococcal Vaccine, Streptococcus Pneumoniae","enrollment":3507},{"nctId":"NCT06790290","phase":"PHASE2","title":"Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventprise Inc.","startDate":"2025-01-27","conditions":"Pneumococcal Disease, Invasive","enrollment":421},{"nctId":"NCT07086677","phase":"PHASE1","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-07-22","conditions":"Streptococcus Pneumoniae","enrollment":372},{"nctId":"NCT06151288","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2023-11-08","conditions":"Pneumococcal Vaccines","enrollment":1015},{"nctId":"NCT06185842","phase":"NA","title":"The Effectiveness of a Lung Health Promotion Program Based on the 5A Self Management Support Model.","status":"COMPLETED","sponsor":"Selcuk University","startDate":"2023-11-21","conditions":"Pulmonary Disease","enrollment":49},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT07025876","phase":"EARLY_PHASE1","title":"PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2023-11-18","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":240},{"nctId":"NCT06514547","phase":"PHASE4","title":"Vaccine Immunity and Inflammation in the Aging Person Living With HIV","status":"RECRUITING","sponsor":"Hennepin Healthcare Research Institute","startDate":"2024-07-08","conditions":"HIV Infections, Age","enrollment":250},{"nctId":"NCT00622843","phase":"PHASE3","title":"Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2002-12","conditions":"HIV Infections, Streptococcus Pneumoniae","enrollment":275},{"nctId":"NCT05879107","phase":"PHASE3","title":"Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-05-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1113},{"nctId":"NCT06474377","phase":"PHASE1","title":"Clinical Trial of PCV24 in Adults","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-06-21","conditions":"Pneumococcal Infectious Disease","enrollment":170},{"nctId":"NCT05691790","phase":"NA","title":"Older People's Preventive Care Utilization","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-10-01","conditions":"Health Communication","enrollment":270},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT03489018","phase":"PHASE4","title":"The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-03-21","conditions":"Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against","enrollment":2100},{"nctId":"NCT06678607","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older","status":"COMPLETED","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2023-11-19","conditions":"Pneumococcal Infectious Disease","enrollment":240},{"nctId":"NCT04875533","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-14","conditions":"Pneumococcal Disease","enrollment":1425},{"nctId":"NCT05425732","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Infection","enrollment":2663},{"nctId":"NCT05420961","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-12","conditions":"Pneumonia, Pneumococcal","enrollment":717},{"nctId":"NCT05875727","phase":"PHASE3","title":"A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-08-16","conditions":"Pneumococcal Disease","enrollment":405},{"nctId":"NCT05297578","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2022-06-15","conditions":"Pneumococcal Vaccines","enrollment":207},{"nctId":"NCT05633992","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-01-10","conditions":"Pneumococcal Disease","enrollment":450},{"nctId":"NCT05464420","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-08-12","conditions":"Pneumococcal Disease","enrollment":2162},{"nctId":"NCT05408429","phase":"PHASE3","title":"Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-06-24","conditions":"Pneumococcal Disease","enrollment":356},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT05266456","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2022-02-22","conditions":"Pneumococcal Vaccines","enrollment":835},{"nctId":"NCT04642079","phase":"PHASE3","title":"Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-12-04","conditions":"Pneumococcal Disease","enrollment":839},{"nctId":"NCT04546425","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-09-09","conditions":"Pneumococcal Disease","enrollment":1258},{"nctId":"NCT04382326","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-05-20","conditions":"Pneumococcal Disease","enrollment":1997},{"nctId":"NCT04665050","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-04","conditions":"Pneumococcal Infection","enrollment":102},{"nctId":"NCT05477693","phase":"PHASE4","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-10-25","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT05731115","phase":"PHASE4","title":"Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-02-27","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT05540028","phase":"PHASE1","title":"Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2022-09-28","conditions":"Pneumococcal Vaccines","enrollment":65},{"nctId":"NCT03565900","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Pneumococcal Infections","enrollment":277},{"nctId":"NCT04379713","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-05-21","conditions":"Pneumococcal Disease","enrollment":1511},{"nctId":"NCT03921424","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Pneumococcal Infections","enrollment":407},{"nctId":"NCT04530838","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-09-16","conditions":"Pneumococcal Disease","enrollment":668},{"nctId":"NCT05767606","phase":"PHASE4","title":"Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2023-03","conditions":"COVID-19, Pneumococcal Infections","enrollment":256},{"nctId":"NCT04887948","phase":"PHASE3","title":"Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-20","conditions":"Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection","enrollment":570},{"nctId":"NCT02851056","phase":"EARLY_PHASE1","title":"Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-09-27","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT04168190","phase":"PHASE1, PHASE2","title":"A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-06","conditions":"Pneumonia, Pneumococcal","enrollment":600},{"nctId":"NCT04989465","phase":"PHASE4","title":"A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-09-10","conditions":"Pneumococcal Infections","enrollment":600},{"nctId":"NCT02049138","phase":"PHASE2","title":"An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01-24","conditions":"Rheumatoid Arthritis","enrollment":493},{"nctId":"NCT04526574","phase":"PHASE3","title":"Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-09-01","conditions":"Pneumococcal Disease","enrollment":1796},{"nctId":"NCT03480802","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-06","conditions":"Pneumococcal Infections","enrollment":302},{"nctId":"NCT04953325","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-07-09","conditions":"COVID-19","enrollment":270},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT03760146","phase":"PHASE3","title":"Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-12-12","conditions":"Pneumococcal Disease","enrollment":3902},{"nctId":"NCT02225587","phase":"PHASE3","title":"Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-28","conditions":"Pneumococcal Infections","enrollment":400},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652},{"nctId":"NCT02279589","phase":"PHASE2","title":"Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-12-04","conditions":"Pneumococcal Infection","enrollment":60},{"nctId":"NCT03835975","phase":"PHASE3","title":"Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-02-12","conditions":"Pneumococcal Disease","enrollment":875},{"nctId":"NCT03547167","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-16","conditions":"Pneumococcal Infections","enrollment":1515}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prevnar20™","Prevnar20®"],"phase":"phase_3","status":"active","brandName":"Prevnar 20 vaccine","genericName":"Prevnar 20 vaccine","companyName":"Sanofi","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prevnar 20 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 20 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults aged 18 years and older, Prevention of pneumococcal pneumonia in adults aged 18 years and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}